Reinsdorf Judith A 4
4 · Nurix Therapeutics, Inc. · Filed May 15, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) Director Judith A. Reinsdorf Receives Award
What Happened Judith A. Reinsdorf, a director of Nurix Therapeutics (NRIX), was granted a derivative award of 31,250 shares on May 15, 2026. The filing shows an acquisition at $0.00 (a granted stock option/award), so no cash changed hands at grant and no shares were sold. This is a compensation/retention-type award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-15; transaction code: A (award/grant).
- Amount: 31,250 shares (derivative award / stock option); acquisition price reported as $0.00.
- Vesting: The option vests 100% on the earlier of the Issuer’s next annual meeting or May 15, 2027, subject to continued service (per footnote).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing timeliness: reported on 2026-05-15 (no indication in the filing excerpt that it was late).
Context This was an equity compensation grant (stock option) that does not represent an immediate purchase or sale of shares. Such grants are common for directors as part of pay/retention and do not by themselves indicate buying or selling intent. The award must vest (and any exercise would be a separate taxable/filing event) before the insider can acquire shares.
Insider Transaction Report
- Award
Director Stock Option (right to buy)
[F1]2026-05-15+31,250→ 31,250 totalExercise: $15.86Exp: 2036-05-14→ Common Stock (31,250 underlying)
Footnotes (1)
- [F1]The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.